A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.
Crizotinib has been studied across 13 research domains including 🔬 Oncology, ⏳ Longevity & Aging, 🫘 Kidney, 🫁 Liver & Detox, 🧠 Focus & Attention. The primary research focus is 🔬 Oncology with 76% of studies addressing this area.
The following compounds share molecular targets with Crizotinib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Crizotinib is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.